Almotriptan – the all-rounder

Compared to the pioneering substance sumatriptan, almotriptan (Almogran) has an even more targeted effect on blood vessels in the meninges. It specifically inhibits the inflammatory processes during migraine attacks in the area of ​​the meninges.

In addition, the absorption into the blood vessel system after the stomach passage is 70 percent higher than with all other triptans. It is therefore reliably absorbed in the stomach after being taken as a tablet and can therefore reliably release the active ingredients and reach the required site of action even in the event of nausea and vomiting. Almotriptan also reduces the typical migraine symptoms of nausea, sensitivity to light and noise.

This leads to a particularly reliable effect.

Almotriptan is very well tolerated. Almotriptan causes fewer side effects, such as chest tightness or heart problems, than sumatriptan.

Almotriptan is supplied in a 12.5 mg tablet.

Since May 1, 2011, it has also been available without a prescription as Dolortriptan.

Special features at a glance

  • Within two hours of taking almotriptan, 64 percent of patients reported a reduction in pain and 37 percent reported complete freedom from pain.
  • The effect starts after just 30 minutes.
  • In addition, the effectiveness of Almotriptan does not decrease over the long term.
  • Recurrent headaches are also less common in patients taking almotriptan (18 to 27 percent) than those taking Riza and sumatriptan (30 to 40 percent).
  • In clinical studies, almotriptan was very well tolerated. Adverse events are no more common with 12.5 mg almotriptan than with placebo.
  • Almotriptan combines many of the advantages of triptans, is quick, gentle and sustainably effective, which earned Almotriptan the nickname “all-rounder”.